Drug profile

The FDA adverse-event record for Canine B Burgdorferi *2 Alu Kb

356 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Canine B Burgdorferi *2 Alu Kb. See the species affected, top reactions, and outcomes below.

356
adverse-event reports
3.9%
death-coded share
Dog
most-reported species
159
Lack of efficacy (bacteria) - Borrelia - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
356
Total Reports
14
Deaths Reported
3.9%
Death Rate

Active Ingredients

Canine B Burgdorferi *2 Alu Kb

Administration Routes

SubcutaneousUnknownOral

Species Affected

Dog 356

Most Affected Breeds

Crossbred Canine/dog 80
Retriever - Labrador 51
Retriever - Golden 36
Shepherd Dog - German 13
Shepherd Dog - Australian 11
Beagle 9
Terrier (unspecified) 7
Shih Tzu 6
Siberian Husky 6
Boxer (German Boxer) 6

Most Reported Reactions

Lack of efficacy (bacteria) - Borrelia 159
Lack of efficacy (bacteria) - NOS 104
Lack of efficacy (tick) 101
Lack of efficacy (ectoparasite) - tick NOS 86
Lack of efficacy (bacteria) - Anaplasma 29
Vomiting 22
Lethargy (see also Central nervous system depression in 'Neurological') 12
Emesis (multiple) 12
Seizure NOS 10
Death by euthanasia 10
Drug dose administration interval too long 10
Injection site lump 9

Outcome Breakdown

Ongoing
241 (67.7%)
Recovered/Normal
78 (21.9%)
Outcome Unknown
22 (6.2%)
Euthanized
10 (2.8%)
Died
4 (1.1%)
Recovered with Sequela
1 (0.3%)

Canine B Burgdorferi *2 Alu Kb Adverse Event Insights

356 reports name Canine B Burgdorferi *2 Alu Kb; 14 recorded a death outcome (3.9% of reported events, not a population-level mortality rate). Active ingredient: Canine B Burgdorferi *2 Alu Kb. Administration routes: Subcutaneous, Unknown, Oral.

By species: Dog (356 reports). By breed: Crossbred Canine/dog (80), Retriever - Labrador (51), Retriever - Golden (36).

Leading clinical signs: Lack of efficacy (bacteria) - Borrelia (159), Lack of efficacy (bacteria) - NOS (104), Lack of efficacy (tick) (101), Lack of efficacy (ectoparasite) - tick NOS (86). Outcome, 356 coded reports: Ongoing leads at 67.7%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.